We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
In mid November, US drugmaker Moderna announced its experimental COVID-19 vaccine was 94.5% effective in preventing the virus. The news comes just a week after Pfizer's vaccine revealed a 90% accuracy rate.
Moderna (MRNA) is a US pharmaceutical and biotechnology company. The company focuses on messenger RNA (mRNA) technology and was among the first to develop a vaccination against COVID-19. Moderna was founded in 2010 and its headquarters are in Cambridge, Massachusetts in the USA.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$65.49 - US$497.49 |
|---|---|
| 50-day moving average | US$413.6259 |
| 200-day moving average | US$253.2295 |
| Target price | US$326 |
| PE ratio | 50.8199 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$8.464 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $430.14
| 1 week (2021-09-16) | -2.39% |
|---|---|
| 1 month (2021-08-26) | 7.45% |
| 3 months (2021-06-25) | 95.57% |
| 6 months (2021-03-26) | 222.73% |
| 1 year (2020-09-25) | 519.17% |
|---|---|
| 2 years (2019-09-26) | 2,532.44% |
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Moderna shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.9 billion (£2.9 billion).
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$7 billion |
|---|---|
| Operating margin TTM | 54.39% |
| Gross profit TTM | US$-574,877,000 |
| Return on assets TTM | 24.3% |
| Return on equity TTM | 72.43% |
| Profit margin | 49.79% |
| Book value | 16.635 |
| Market capitalisation | US$173.6 billion |
TTM: trailing 12 months
There are currently 15.4 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 18.1% down from 18.8 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 24.4 million). Moderna's SIR currently stands at 0.63. In other words for every 100,000 Moderna shares traded daily on the market, roughly 630 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 30 shares are currently held short) or 0.04% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
We're not expecting Moderna to pay a dividend over the next 12 months.
Over the last 12 months, Moderna's shares have ranged in value from as little as US$65.49 up to US$497.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4792. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing Incannex Healthcare from Australia.
Steps to owning and managing Scotts Miracle Go shares from Australia.
Shares in the national carrier are up 30% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the Frax Share (FXS) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the ShareToken (SHR) token as well as a list of exchanges you can trade it on.
Steps to owning and managing Rubicon Water shares.
Steps to owning and managing Endeavour Group Limited shares from Australia.
Steps to owning and managing BetaShares Legg Mason Emerging Markets Fund (Managed Fund) ETF units.
Steps to owning and managing eInvest Future Impact Small Caps Fund (Managed Fund) ETF units.
Steps to owning and managing VanEck Vectors MSCI International Value ETF units.
